Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
UBS
Teva
Queensland Health
Merck
Colorcon

Generated: May 26, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,761,910

« Back to Dashboard

Summary for Patent: 6,761,910
Title: Pharmaceutical composition for the treatment of acute disorders
Abstract:A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.
Inventor(s): Pettersson; Anders (Kode, SE), Nystrom; Christer (Uppsala, SE)
Assignee: Diabact AB (Uppsala, SE)
Application Number:09/787,888
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,761,910
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,761,910
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 6,761,910

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-001 Jan 7, 2011 AB RX Yes No ➤ Sign Up ➤ Sign Up Y MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER ➤ Sign Up
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-002 Jan 7, 2011 AB RX Yes No ➤ Sign Up ➤ Sign Up Y MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER ➤ Sign Up
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-003 Jan 7, 2011 AB RX Yes No ➤ Sign Up ➤ Sign Up Y MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,761,910

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9803240Sep 24, 1998
PCT Information
PCT FiledSeptember 24, 1999PCT Application Number:PCT/SE99/01687
PCT Publication Date:March 30, 2000PCT Publication Number: WO00/16750

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Teva
Merck
Covington
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.